Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Zimmer Biomet to $110 from $113 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet management to meet with BTIG
- Omnicell names Nnamdi Njoku as new COO
- FDA issues alert for increased risk of fracture after surgery with CPT System
- Zimmer Biomet price target lowered to $120 from $125 at JPMorgan
- Zimmer Biomet price target lowered to $112 from $117 at Truist